Table 1 Clinical and biologic characteristics of the patients in two cohorts
From: Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas
| Variables | Training cohort (n = 115) | Validation cohort (n = 58) | P-value |
|---|---|---|---|
| Basic results | |||
| Age, years | 54 (43.0, 65.0) | 52 (45.8, 61.2) | 0.611 |
| Sex (%) | |||
| Female | 35 (30.4) | 19 (32.8) | 0.755 |
| Male | 80 (69.6) | 39 (67.2) | |
| Subtype composition | |||
| ENKTL | 40 (34.8) | 24 (41.4) | 0.037 |
| PTCL-NOS | 32 (27.8) | 14 (24.1) | |
| AITL | 25 (21.7) | 4 (6.9) | |
| ALCL | 8 (7.0) | 11 (19.0) | |
| EATCL | 6 (5.2) | 2 (3.4) | |
| MF/SPTCL | 4 (3.5) | 3 (5.2) | |
| ECOG score (%) | |||
| < 2 | 62 (53.9) | 38 (65.5) | 0.145 |
| ≥ 2 | 53 (46.1) | 20 (34.5) | |
| BM involvement (%) | |||
| Absence | 86 (74.8) | 47 (81.0) | 0.357 |
| Presence | 29 (25.2) | 11 (19.0) | |
| Extranodal sites (%) | |||
| < 2 | 61 (53.0) | 32 (55.2) | 0.791 |
| ≥ 2 | 54 (47.0) | 26 (44.8) | |
| Ann Arbor stage (%) | |||
| I/II | 44 (38.3) | 25 (43.1) | 0.539 |
| III/IV | 71 (61.7) | 33 (56.9) | |
| B symptoms (%) | |||
| Absence | 41 (35.7) | 27 (46.6) | 0.166 |
| Presence | 74 (64.3) | 31 (53.4) | |
| Serological results | |||
| LDH, U/L | 243.0 (183.6, 388.0) | 224.3 (178.9, 320.6) | 0.433 |
| Β2-MG, mg/L | 3.0 (2.2, 3.8) | 2.8 (2.2, 3.6) | 0.424 |
| TC, mmol/L | 4.0 (3.2, 4.7) | 4.1 (3.5, 5.1) | 0.087 |
| HDL-C, mmol/L | 1.0 (0.8, 1.2) | 1.1 (0.9, 1.3) | 0.041 |
| TG, mmol/L | 1.3 (1.0,1.7) | 1.2 (0.8,1.8) | 0.375 |
| Clinical scoring systems | |||
| IPI (%) | |||
| Low risk | 45 (39.1) | 24 (41.4) | 0.819 |
| Low-intermediate risk | 13 (11.3) | 9 (15.5) | |
| Intermediate-high risk | 25 (21.8) | 11 (19.0) | |
| High risk | 32 (27.8) | 14 (24.1) | |
| Treatment | |||
| Therapy (%) | |||
| CT alone | 60 (52.2) | 17 (29.3) | 0.014 |
| RT alone | 8 (6.9) | 4 (6.9) | |
| CT + RT | 18 (15.7) | 13 (22.4) | |
| CT + HDACi | 21 (18.3) | 22 (37.9) | |
| CT + HSCT | 8 (6.9) | 2 (3.5) | |
| Outcomes | |||
| Therapeutic response (%) | |||
| CR/PR | 30 (26.1) | 24 (41.4) | 0.040 |
| SD/PD | 85 (73.9) | 34 (58.6) | |
| Death (%) | 67 (58.3) | 16 (27.6) | 0.000 |
| Median OS | 21.0 (9.0, 55.0) | 13.5 (5.4, 17.0) | 0.000 |
| Progression and NRM (%) | 78 (67.8) | 26 (44.8) | 0.004 |
| Median PFS | 12.0 (3.5, 41.0) | 9.8 (3.9, 15.6) | 0.038 |